Cs 2500 coagulation analyzer

Various doses of UFH (Heparin LEO, Ballerup, Denmark) were spiked into each PPP sample to obtain final concentrations of 0.2, 0.4, 0.6, 0.8, and 1.0 IU/ml. The spiked samples were aliquoted and stored at −80°C until required.
Anti‐FXa activity of all spiked samples was determined using Biophen Heparin LRT reagent (Hyphen Biomed, Neuville‐sur‐Oise, France). This assay was performed using the Sysmex CS‐2500 coagulation analyzer (Sysmex Corporation, Kobe, Japan), according to the industrial protocol and calibrated with Biophen Heparin calibrators. These spiked samples were prepared in the same laboratory throughout the study.

For aPTT tests, Dade Actin FSL and Dade Actin FS aPTT reagents (Siemens Healthineers) were used for aPTT screening and confirmatory tests, respectively. LA1 Screening and LA2 Confirmation reagents (Siemens Healthineers) were employed for dRVVT screening and confirmatory tests, respectively. Additional coagulation indices measured prior to LA testing, including prothrombin time, thrombin time, and fibrinogen level (Clauss method), were measured by the same analyzer using Thromborel S, Thromboclotin, and Dade Innovin thrombin reagents (Siemens Healthineers), respectively. In a 1:1 mixing test, a commercial standard human plasma (Siemens Healthineers) was used as the normal pooled plasma (NPP). All assays were performed on a Sysmex CS−2500 Coagulation analyzer (Sysmex).